DCC shares have jumped 17% in the FTSE 100 index after the Dublin-based conglomerate announced plans to focus on its energy ...

Also in today’s newsletter, US regulators plan to investigate Microsoft’s cloud business, and Disney-Reliance Indian media giant says TV ‘is not dead’ ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, Smith ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

Pharmaceutical giant AstraZeneca has again raised its annual sales and profit forecast, following a strong third-quarter ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a ...